

Rich and diversified pipeline

	Asset	Indication	Rights	Preclinical	Phase 1	Phase 2	Phase 3	Upcoming Catalyst
Oncology								
Off-the-shelf	VB10.16	HPV16+ cervical cancer	1	[Progress bar: ~80%]				Initiate trial (Q4 2023)
		HPV16+ head and neck cancer	2	[Progress bar: ~60%]				Dose level recommendation (H2 2024)
		HPV16+ locally advanced cervical cancer	2	[Progress bar: ~90%]				Protocol in development
	Regeneron programs	Undisclosed	3	[Progress bar: ~40%]				
	NYK011	Colorectal: pre-cancerous polyps to cancer	3	[Progress bar: ~40%]				
Individualized	VB10.NEO	Melanoma, lung, bladder, renal, head and neck cancer; locally advanced and metastatic tumors	4	[Progress bar: ~80%]				
		Locally advanced and metastatic tumors	4	[Progress bar: ~60%]				
Infectious Disease								
	Regeneron programs	Undisclosed	3	[Progress bar: ~40%]				
Autoimmune								
	Internal	Undisclosed	3	[Progress bar: ~40%]				Update (H2 2024)

1. Wholly-owned by Nykode. Potentially registrational. Roche supplies atezolizumab; 2. Wholly-owned by Nykode. Merck (MSD) supplies pembrolizumab; 3. Collaboration with Regeneron; 4. Genentech has an exclusive license to VB10.NEO.